Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Transgenomic, Inc. Acquires Exclusive Worldwide License to Predictive Markers for Cancer Drug Response

May 26, 2011 By Bio-Medicine.Org

OMAHA, Neb., May 26, 2011 /PRNewswire/ — Transgenomic,
Inc.
(OTC/BB: TBIO) announced today that it has acquired an
exclusive worldwide license to Montefiore Medical Center’s (Bronx,
NY, US) patent application, “Method of Determining the Sensitivity
of Cancer Cells to EGFR Inhibitors including cetuximab, panitumumab
and erlotinib”.  The invention relates to the discovery by
Montefiore scientists and collaborators that tumor-specific
mutations in the genes PIK3CA and PTEN can aid in
predicting patient non-response to epidermal growth factor receptor
(EGFR) inhibitors, a widely prescribed class of cancer drugs.

Transgenomic is incorporating the PIK3CA and PTEN
gene assays into its rapidly expanding menu of cancer profiling
tests available through its clinical reference laboratories and is
developing testing kits for sale to other labs. Testing of these
genes is also being offered to support drug development research by
pharmaceutical companies that have been expressing great interest
in these genes and in Transgenomic’s proprietary, ultra-sensitive
mutation-detection technologies. At the American Association for
Cancer Research meeting in April of this year, Transgenomic
described methods for detecting tumor-specific mutations at such
low levels that it may be possible to identify them in patients’
blood samples, not just in surgically obtained tumor tissues.

“This exclusive license from Montefiore strengthens our
cancer-related diagnostic test portfolio and is integral to the
continued development of our leadership position in oncology,” said
Craig Tuttle, CEO of Transgenomic. “At Transgenomic, we are
uniquely equipped to maximize the value of these genetic
discoveries by combining them with the unparalleled sensitivity of
our proprietary mutation-detection technologies. Our exclusive
access to this new intellectual property will enable us to provide
the most comprehensive analysis for predicting response to ca

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech